 |
SYDNEY, June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298).
The data is the subject of a poster presentation at the Annual Meeting...
UNSW Founders, Australia’s most recommended startup accelerator, has partnered with fund manager Luminary Partners to invest $200,000 each into 18...
The present business environment imposes stronger requirements on Australian organizations to match the fast-paced digital-first economy requireme...
Managing data responsibly and effectively for the AI age can give organisations a strong competitive advantage, but many are failing to harness th...
Zyft appoints new CEO, Richard Stevens, to lead the latest Waller Group success story, valued at $30 million SYDNEY, 28 April 2025: Zyft, the lea...
A little-known legal amendment is being leveraged by savvy New Zealanders and expat Brits to supercharge their retirement savings. Not many peop...
New Zealand specialist doctors now have access to Artificial Intelligence technology to help reduce patient wait times and experts say it could be...
